Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ract in a process that ultimately results in the persistent inflammation underlying IBD. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the GI system.

"Current approaches to the treatment of Crohn's disease often result in serious side effects, especially following long-term use of these drugs," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "These results suggest that Traficet-EN has the potential to keep Crohn's patients in remission without complications such as broad immunosuppression associated with current therapies."

"Data generated from these two studies are groundbreaking in nature and have the potential to revolutionize the way Crohn's disease and ulcerative colitis are treated," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We are particularly pleased that we have for the first time definitively identified the CCR9 chemokine ligand in the large bowel which will broaden the scope of digestive tract disorders that Traficet-EN could potentially treat successfully."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

The randomized, placebo-controlled, double-blind clinical trial of 436 patients is comprised of three discrete periods which allows for evaluation of efficacy and safety of Traficet-EN in inducing a cl
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Boston Scientific Corporation (NYSE: ... to purchase the Interventional business of Bayer AG. ... to offer physicians and healthcare systems a more ... conditions. The addition of the Bayer ... the Boston Scientific strategy to provide a comprehensive ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on its ... device market, Frost & Sullivan recognizes Novian Health, ... Sullivan Award for Technology Innovation Leadership. Novian Health ... and malignant tumors with its proprietary technology, Novilase ... a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation ...
(Date:9/2/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the Morgan Stanley Global ... a.m. ET. The conference will be held at the ... City . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... 1 Clinicians at Institut Catala d,Oncologia (ICO) in Barcelona ... RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate cancer ... country to receive the fast and efficient treatment. , ... "The treatment went very well and the patient ...
... SAN DIEGO , June 1, 2010 Amylin Pharmaceuticals, ... , MD has been appointed Senior Vice President, Research and Development. ... Chief Medical Officer. These leadership changes will strengthen the Company,s focus ... its late-stage development programs, both important value drivers for the Company. ...
Cached Medicine Technology:Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 2Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 3Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 5
(Date:9/2/2014)... September 02, 2014 Eric Jimenez and ... Me , a revolutionary makeup application device. Designed to ... proven innovation in the palm of women’s hands to ... secret to Color Me’s success lies in its patented ... a rate of 15,000 pulses per minute, the device ...
(Date:9/2/2014)... NJ (PRWEB) September 02, 2014 BESLER ... protection services for hospitals, is pleased to announce that ... in-depth review of the FY 2015 Hospital Inpatient ... the Centers for Medicare & Medicaid Services. , “Hospitals ... variety of reasons,” said Jonathan Besler, BESLER’s President and ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the world-famous ... Lee has the unique distinction of being the first and ... history, Misty Lee is the first female magician to hold ... staff Medium at the Magic Castle,” says Misty Lee. “Even ... being at the Magic Castle, I can fascinate guests in ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
Breaking Medicine News(10 mins):Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5
... who fear their own death say they are more prepared ... whom further medical treatment is considered futile,// reveals research published ... Archives of Disease in Childhood. ,The findings ... in the care of sick newborns (neonatologists) across Australia and ...
... low numbers of organ donors in Australia is an ongoing ... ,In the latest edition of the Medical Journal ... of the issues surrounding organ donation in Australia. ... the second the impact of public education campaigns on organ ...
... According to a latest Government data, there is an alarming ... this could be linked to the plummeting sale of// antidepressants. ... and Prevention (CDC) also indicated that youth in their late ... Food and Drug Administration had issued a black box warning ...
... using a sophisticated form of analysis called meta-analysis, in which ... for// possibly preventing up to half of the cases of ... in the United States. The work was conducted by a ... Center at University of California, San Diego (UCSD), and colleagues ...
... the United States and a growing epidemic worldwide. Now, ... able to make a valuable contribution to an overall ... ,A study published in the Journal of Vertebral ... when used as part of an integrative treatment in ...
... there is a pronounced increase of mental illnesses ... spectrum disorders, obsessive// compulsive disorders and hyperkinetic illnesses. ... Pediatric and Adolescent Medicine. ,Researches are ... to the increased awareness about these diseases or ...
Cached Medicine News:Health News:Doctors’ Own Fear of Death Linked to Hastening Death of Very Sick Newborn 2Health News:The Search for Organ Donors 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Research Explores Chiropractic's Effect on Diabetes 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: